CASI - CASI Pharmaceuticals Inc

-

$undefined

N/A

(N/A)

CASI Pharmaceuticals Inc NasdaqCM:CASI CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company's hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investigative product; BI-1206, an novel anti-Fc?RIIB antibody for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. It has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Location: 1701-1702, China Central Office Tower 1, Beijing, 100025, China | Website: https://www.casipharmaceuticals.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

36.07M

Cash

16.09M

Avg Qtr Burn

-7.306M

Short % of Float

0.27%

Insider Ownership

41.45%

Institutional Own.

15.98%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Phase 2

Update

BI-1206 (Anti-FcyRIIB antibody) + rituximab Details
Blood cancer, Non-Hodgkin lymphoma, Solid tumor/s, Cancer

Phase 1/2

Data readout

CID-103 Details
Immune Thrombocytopenia (ITP)

Phase 1/2

Data readout

CB-5339 Details
Multiple myeloma

Phase 1

Data readout